DK1461034T3 - Substituerede imidazolidiner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament eller diagnostikum, samt medikament indeholdende dem - Google Patents

Substituerede imidazolidiner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament eller diagnostikum, samt medikament indeholdende dem

Info

Publication number
DK1461034T3
DK1461034T3 DK02796586T DK02796586T DK1461034T3 DK 1461034 T3 DK1461034 T3 DK 1461034T3 DK 02796586 T DK02796586 T DK 02796586T DK 02796586 T DK02796586 T DK 02796586T DK 1461034 T3 DK1461034 T3 DK 1461034T3
Authority
DK
Denmark
Prior art keywords
diagnostic
drug
processes
preparation
well
Prior art date
Application number
DK02796586T
Other languages
Danish (da)
English (en)
Inventor
Uwe Heinelt
Hans-Jochen Lang
Armin Hofmeister
Klaus Wirth
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1461034T3 publication Critical patent/DK1461034T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK02796586T 2001-12-21 2002-12-09 Substituerede imidazolidiner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament eller diagnostikum, samt medikament indeholdende dem DK1461034T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10163239A DE10163239A1 (de) 2001-12-21 2001-12-21 Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament
PCT/EP2002/013921 WO2003053434A1 (de) 2001-12-21 2002-12-09 Substituierte imidazolidine, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie enthaltendes medikament

Publications (1)

Publication Number Publication Date
DK1461034T3 true DK1461034T3 (da) 2007-03-26

Family

ID=7710363

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02796586T DK1461034T3 (da) 2001-12-21 2002-12-09 Substituerede imidazolidiner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament eller diagnostikum, samt medikament indeholdende dem

Country Status (27)

Country Link
EP (1) EP1461034B1 (no)
JP (1) JP4571803B2 (no)
KR (1) KR100959031B1 (no)
CN (1) CN100339079C (no)
AR (1) AR037932A1 (no)
AT (1) ATE345797T1 (no)
AU (1) AU2002361990B2 (no)
BR (1) BR0215154A (no)
CA (1) CA2470856A1 (no)
CO (1) CO5590925A2 (no)
DE (2) DE10163239A1 (no)
DK (1) DK1461034T3 (no)
ES (1) ES2275945T3 (no)
HR (1) HRP20040573A2 (no)
HU (1) HUP0600836A2 (no)
IL (2) IL162562A0 (no)
MA (1) MA27149A1 (no)
MX (1) MXPA04005388A (no)
MY (1) MY134344A (no)
NO (1) NO20043009L (no)
PE (1) PE20030741A1 (no)
PL (1) PL368940A1 (no)
RS (1) RS53204A (no)
RU (1) RU2004122415A (no)
TW (1) TW200305408A (no)
WO (1) WO2003053434A1 (no)
ZA (1) ZA200404149B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10323701A1 (de) 2003-05-22 2004-12-23 Aventis Pharma Deutschland Gmbh Verfahren zur Synthese heterocyclischer Verbindungen
CA2531167C (en) 2003-06-30 2012-05-22 Sumitomo Chemical Company, Limited Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst
DE10341240A1 (de) * 2003-09-08 2005-04-07 Aventis Pharma Deutschland Gmbh Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
BR112017000691B1 (pt) 2014-07-25 2023-02-14 Taisho Pharmaceutical Co., Ltd Feniltetra-hidroisoquinolina substituído com heteroari-la, seu uso, medicamento, inibidores de nhe3, de absorção de sódio e de absorção de fósforo, promotor de secre-ção de água intestinal e fármaco profilático ou terapêu-tico para constipação

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3202660A (en) * 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
US3236857A (en) * 1961-10-09 1966-02-22 Boehringer Sohn Ingelheim 2-(phenyl-amino)-1, 3-diazacyclopentene-(2) substitution products
EP0070084A3 (en) * 1981-04-24 1983-02-16 Beecham Group Plc Imidazoline derivatives
DE3712385A1 (de) * 1987-04-11 1988-10-27 Boehringer Ingelheim Kg 2-(phenylimino)imidazolidine
GB9313330D0 (en) * 1993-06-28 1993-08-11 Fujisawa Pharmaceutical Co New compound and its preparation
EP0639573A1 (de) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
DE4328869A1 (de) * 1993-08-27 1995-03-02 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
KR100257129B1 (ko) * 1993-09-11 2000-05-15 성재갑 신규 세팔로스포린계 항생제 및 이의 제조방법
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
DE19548812A1 (de) * 1995-12-27 1997-07-03 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation
DE19633966A1 (de) * 1996-08-22 1998-02-26 Hoechst Ag Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DK0966465T3 (da) * 1997-03-14 2003-10-20 Vertex Pharma Inhibitorer af IMPDH-enzymer
DE19945302A1 (de) * 1999-09-22 2001-03-29 Merck Patent Gmbh Biphenylderivate als NHE-3-Inhibitoren
DE19950898A1 (de) * 1999-10-22 2001-04-26 Aventis Pharma Gmbh Heterocyclisch substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19960204A1 (de) * 1999-12-14 2001-06-28 Aventis Pharma Gmbh Substituierte Norlbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE10015248A1 (de) * 2000-03-28 2001-10-04 Merck Patent Gmbh Bisamidino-Verbindungen als NHE-3 Inhibitoren
DE10019062A1 (de) * 2000-04-18 2001-10-25 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren
DE10060292A1 (de) * 2000-12-05 2002-06-20 Aventis Pharma Gmbh Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament

Also Published As

Publication number Publication date
WO2003053434A1 (de) 2003-07-03
BR0215154A (pt) 2004-10-19
ZA200404149B (en) 2006-05-31
MY134344A (en) 2007-12-31
CA2470856A1 (en) 2003-07-03
IL162562A0 (en) 2005-11-20
RS53204A (en) 2006-10-27
AU2002361990B2 (en) 2008-10-09
HRP20040573A2 (en) 2004-10-31
ES2275945T3 (es) 2007-06-16
HUP0600836A2 (en) 2008-04-28
EP1461034A1 (de) 2004-09-29
EP1461034B1 (de) 2006-11-22
RU2004122415A (ru) 2005-03-27
AU2002361990A1 (en) 2003-07-09
KR100959031B1 (ko) 2010-05-20
JP2005516947A (ja) 2005-06-09
KR20040068322A (ko) 2004-07-30
DE10163239A1 (de) 2003-07-10
CN100339079C (zh) 2007-09-26
MA27149A1 (fr) 2005-01-03
TW200305408A (en) 2003-11-01
AR037932A1 (es) 2004-12-22
ATE345797T1 (de) 2006-12-15
NO20043009L (no) 2004-07-15
JP4571803B2 (ja) 2010-10-27
DE50208809D1 (de) 2007-01-04
PE20030741A1 (es) 2003-09-29
CN1606440A (zh) 2005-04-13
CO5590925A2 (es) 2005-12-30
MXPA04005388A (es) 2004-10-11
IL162562A (en) 2009-12-24
PL368940A1 (en) 2005-04-04

Similar Documents

Publication Publication Date Title
NO20032733D0 (no) Difenyl azetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene samt deres anvendelse
NO20032735D0 (no) Difenyl azetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene samt deres anvendelse
NO20034149D0 (no) Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
NO20040678L (no) Aminoalkyl-substituert aromatiske bicykliske forbindelser, fremgangsmate for deres fremstilling og deres anvendelse som legemidler.
DK1732917T3 (da) Udvalgte CGRP-antagonister, fremgangsmåde til fremstilling deraf, samt anvendelse deraf som lægemiddel
NO20054329D0 (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
DK1453810T3 (da) Substituerede 4-phenyltetrahydroisoquinoliner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament indeholdende samme
DK1838315T3 (da) Substituerede 4-phenyltetrahydroisoquinoliner, fremgangsmåde til fremstilling heraf, deres anvendelse som medikament samt medikamenter indeholdende dem
NO20064808L (no) Orale matrixformuleringer med licarbazepin
NO20023643L (no) Forbindelser som har antitumoraktivitet, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger som inneholderdem
NO20022801D0 (no) Substituerte norbornylaminoderivater, fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikumsåvel som medikamenter inneholdende disse
NO20064783L (no) Opplosningstabeletter med licarbazepin
DK1509498T3 (da) Pentafloursulfanyl-benzoylguanidiner, fremgangsmåder til fremstilling deraf, anvendelse deraf som medikament eller diagnostikum samt medikament indeholdende dem
ITMI20031867A1 (it) Procedimento per riempire contenitori farmaceutici come ampolle, fiale o similari.
NO972433L (no) Substituerte 2-naftoylguanidiner, fremgangsmåter for deres fremstilling, deres anvendelse som medikament eller diagnostikum samt medikamenter inneholdende forbindelsene
NO952596D0 (no) Orto-aminosubstituerte benzoylguandiner, fremgangsmåter for deres fremstilling, deres anvendelse som legemiddel eller diagnostikum såvel som medikamenter som inneholder dem
NO980694D0 (no) Sulfonamidsubstituerte kromaner, fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostika såvel som medikamenter inneholdende dem
DK1118610T3 (da) Benzensulfonamid-derivater, fremgangsmåde til fremstilling heraf samt farmaceutiske sammensætninger indeholdende derivaterne
DK1513834T3 (da) Substituerede thiophener, fremgangsmåde til deres fremstilling, deres anvendelse som medikament eller diagnostikum samt medikament, som indeholder dem
NO984476D0 (no) Sulfonamidsubstituerte kromaner, fremgangsmÕte for fremstilling derav, deres anvendelse som medikament samt farmas°ytiske preparater inneholdende forbindelsene
DK1461034T3 (da) Substituerede imidazolidiner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament eller diagnostikum, samt medikament indeholdende dem
DK1097140T3 (da) Imidazolderivater med biphenylsubstitution, fremgangsmåde til deres fremstilling, deres anvendelse som lægemiddel eller diagnostikum og lægemiddel som indeholder dem
NO983577D0 (no) Sulfonamidsubstituerte forbindelser, fremgangsmåter for deres fremstilling, deres anvendelse som medikament eller diagnostikum, samt medikament inneholdende forbindelsen
NO985023L (no) Sulfonamidsubstituerte benzopyranderivater, fremgangsmÕter for deres fremstilling, deres anvendelse som medikament samt farmas°ytiske preparater inneholdende forbindelsene